• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Multigenetic pharmacogenomics-guided treatment more effective for treatment of schizophrenia

bySoroush NedaieandAlex Chan
October 15, 2023
in Neurology, Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. This randomized clinical trial demonstrated that multigenetic pharmacogenomics-guided treatment (MPGT) had higher response and remission rates in the treatment of schizophrenia compared with treatment as usual (TAU).

Evidence Rating Level: 1 (Excellent)

Schizophrenia—a condition characterized by disruptions in various mental modalities—affects approximately 24 million people globally and imposes a significant disease burden. First-line treatment with antipsychotics is effective for only 20-50% of patients, often leading to a trial-and-error approach to finding an effective treatment. This randomized clinical trial aims to evaluate the efficacy of MPGT in hospitalized men with schizophrenia compared with TAU. 210 male inpatients in Guiyang, China with a diagnosis of schizophrenia were enrolled and randomized in a 1:1 ratio, with both participants and raters masked to the allocation. 113 patients received MPGT, medication regimens tailored to their genetic profiles, and 97 received TAU. MPGT was associated with a significantly greater reduction in the Positive and Negative Syndrome Scale (PANSS) score than TAU at week 12 (83.5% vs 76.1%; P = .001). The response rates, defined as a 20% or greater reduction in PANSS scores, at the end of week 6 were significantly higher in the MPGT group compared to the TAU group (adjusted odds ratio, 2.48; 95% CI, 1.28-4.80; P = .01). Symptomatic remission rates, defined as a PANSS total score of 70 or less, were also higher in the MPGT group (adjusted odds ratio, 2.03; 95% CI, 1.11-3.60; P = .02). While this study is limited by the inclusion of only male Chinese Han patients, these findings suggest that MPGT proved superior to TAU in treating schizophrenia patients, indicating that multigenetic pharmacogenomic testing could be a valuable tool for guiding schizophrenia treatment.

Click to read the study in JAMA Network Open

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis

Mixed reality exposure therapy may have a role in obsessive-compulsive disorder

Physical disability and psychological distress demonstrate marked progression after diagnosis of cancer

Tags: geneticspharmacotherapypsychiatryschizophrenia
Previous Post

Generative artificial intelligence comparable in terms of clinical accuracy and report quality for chest radiographs

Next Post

2 Minute Medicine Rewind October 16, 2023

RelatedReports

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Chronic Disease

Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis

June 12, 2025
Chronic Disease

Mixed reality exposure therapy may have a role in obsessive-compulsive disorder

June 1, 2025
AI Roundup

Physical disability and psychological distress demonstrate marked progression after diagnosis of cancer

May 28, 2025
American Academy of Pediatrics recommends standards for adverse event disclosures
Weekly Rewinds

2 Minute Medicine Rewind May 26, 2025

May 26, 2025
Next Post
Pediatric palliative care outcome measures often miss quality of life

2 Minute Medicine Rewind October 16, 2023

High incidence of cognitive impairment associated with colorectal cancer

Spiritual well-being may be associated with improvements in pain intensity and catastrophizing in patients with chronic pain

Unmet healthcare need in adolescence linked to poor adult outcomes

The Bipolar-at-risk criteria may help screen for young individuals at risk of bipolar disorder

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis
  • Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer
  • Dapagliflozin may improve outcomes in patients with metabolic dysfunction-associated steatohepatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.